Literature DB >> 9268149

Disruption of the varicella-zoster virus dUTPase and the adjacent ORF9A gene results in impaired growth and reduced syncytia formation in vitro.

J Ross1, M Williams, J I Cohen.   

Abstract

Varicella-zoster virus (VZV) open reading frame 8 (ORF8) is predicted to encode the viral dUTPase and the adjacent gene, ORF9A, is thought to encode a membrane protein homologous to HSV-1 UL49.5. A fusion protein, in which the amino portion of glutathione-S-transferase was fused to amino acids 5 to 396 of VZV ORF8 protein, had dUTPase activity in vitro. Construction of a mutant VZV with stop codons or a deletion in the ORF8 gene resulted in loss of viral dUTPase activity. Antibody to VZV ORF9A protein demonstrated a 7-kDa protein located in the membranes of virus-infected cells. Insertion of stop codons into VZV ORF9A resulted in VZV that produced smaller plaques than parental virus. Inactivation of both VZV ORF8 and ORF9A resulted in a virus that grew to lower titers and was impaired for syncytia formation when compared to parental virus. In contrast, a similar mutation in HSV-1 has no effect on growth of the virus in vitro. These results identify loci in the VZV genome that are required for a syncytial phenotype in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9268149     DOI: 10.1006/viro.1997.8652

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  38 in total

1.  Evolution and horizontal transfer of dUTPase-encoding genes in viruses and their hosts.

Authors:  A M Baldo; M A McClure
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus.

Authors:  Yasuyuki Gomi; Hiroki Sunamachi; Yasuko Mori; Kazuhiro Nagaike; Michiaki Takahashi; Koichi Yamanishi
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73).

Authors:  M Mach; B Kropff; P Dal Monte; W Britt
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  The carboxy-terminal domain of glycoprotein N of human cytomegalovirus is required for virion morphogenesis.

Authors:  Michael Mach; Karolina Osinski; Barbara Kropff; Ursula Schloetzer-Schrehardt; Magdalena Krzyzaniak; William Britt
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  The ubiquitous cellular transcriptional factor USF targets the varicella-zoster virus open reading frame 10 promoter and determines virulence in human skin xenografts in SCIDhu mice in vivo.

Authors:  Xibing Che; Barbara Berarducci; Marvin Sommer; William T Ruyechan; Ann M Arvin
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

6.  The Epstein-Barr virus (EBV) gN homolog BLRF1 encodes a 15-kilodalton glycoprotein that cannot be authentically processed unless it is coexpressed with the EBV gM homolog BBRF3.

Authors:  C M Lake; S J Molesworth; L M Hutt-Fletcher
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 7.  Review: The neurobiology of varicella zoster virus infection.

Authors:  D Gilden; R Mahalingam; M A Nagel; S Pugazhenthi; R J Cohrs
Journal:  Neuropathol Appl Neurobiol       Date:  2011-08       Impact factor: 8.090

8.  Array analysis of viral gene transcription during lytic infection of cells in tissue culture with Varicella-Zoster virus.

Authors:  Randall J Cohrs; Michael P Hurley; Donald H Gilden
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor.

Authors:  Zhen Zhang; Anca Selariu; Charles Warden; Grace Huang; Ying Huang; Oluleke Zaccheus; Tong Cheng; Ningshao Xia; Hua Zhu
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

10.  Complete DNA sequences of two oka strain varicella-zoster virus genomes.

Authors:  Sueli L Tillieux; Wendy S Halsey; Elizabeth S Thomas; John J Voycik; Ganesh M Sathe; Ventzislav Vassilev
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.